As most readers would know, I personally consider Mountain Pass to be a bit of a "Dog's breakfast" when it comes to Rare Earth operations.
However, they are now producing and selling "Product" so even though their MC is IMO overvalued, it is now possible to work out what the Markets considers to be a reasonable PE Ratio for them ONCE they get into full swing.
From those fools:Assuming all goes well and the company hits the targets analysts have set for it, 2021 could be the year MP earns its first full-year profit ($0.44 per share). By 2023, that number could triple to $1.33 per share, according to estimates collected by S&P Global Market Intelligence.
But is MP Materials' stock worth 33.3 times the profit the company might earn two years from now, as its current share price implies? That's a question value stock investors will have to answer for themselves.
"33.3" Remember that number for when Pensana's Business Plan is eventually published,
IMO Longonjo/Saltend is going to be a far more robust and profitable operation than MP and we are probably already closer (time wise) to producing Nd.Pr Oxides than they are !
- Forums
- ASX - By Stock
- PM8
- Share price - General Discussion
Share price - General Discussion, page-2755
-
-
- There are more pages in this discussion • 505 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PM8 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online